Colon Cancer Archives - Cancer Therapy Advisor

ASCO 2023

Neoadjuvant Chemo Appears No Better Than Upfront Surgery for Colon Cancer

By

Colby Stong

June 6, 2023

Neoadjuvant chemotherapy does not improve survival outcomes vs upfront surgery in patients with locally advanced colon cancer, a phase 3 trial suggests.

Gastrointestinal Cancers

HIPEC With Mitomycin C Improves Locoregional Control in Colon Cancer

By

Leah Lawrence

May 15, 2023

Adding HIPEC and mitomycin C to surgical resection improves locoregional control in patients with locally advanced colon cancer, a study suggests.

Gastrointestinal Cancers

Physical Activity Linked to Lower Risk of Colon Cancer Recurrence

April 11, 2023

Postoperative physical activity is associated with improved outcomes in patients with stage III colon cancer, a study suggests.

Gastrointestinal Cancers

ctDNA Testing in Colorectal Cancer Deemed Promising but Not Ready for Prime Time

By

Alan P. Lyss, MD

March 10, 2023

Studies suggest that ctDNA testing has prognostic value in colorectal cancer, but more research is needed before it can be used in practice.

Cryopreserved platelets may reduce bleeding in patients with thrombocytopenia.

Gastrointestinal Cancers

Inflammation After Colon Cancer Surgery Tied to Worse Outcomes

By

Leah Lawrence

February 3, 2023

Elevated levels of inflammatory biomarkers are associated with worse outcomes for patients with stage III colon cancer, a study suggests.

Gastrointestinal Cancers

Neoadjuvant Chemotherapy Improves Colon Cancer Outcomes

February 2, 2023

Six weeks of neoadjuvant chemotherapy was associated with a higher rate of complete resection and a lower rate of disease recurrence.

General Oncology

Exercise Intervention During Chemotherapy Beneficial

October 21, 2022

Exercise during chemotherapy may preserve cardiorespiratory fitness, a study suggests.

ESMO 2022

Neoadjuvant Nivolumab-Ipilimumab Could Be New Standard Care in dMMR Colon Cancer

By

Vicki Moore, PhD

September 11, 2022

Neoadjuvant nivolumab and ipilimumab produced an “unprecedented” major pathologic response rate in the NICHE-2 study, according to the lead study author.